Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Mitochondrial activators and GH-axis secretagogues compared: MOTS-c, Epitalon, CJC-1295, and Ipamorelin. Independent COA quality data, key study summaries, and current regulatory status.
2 of 4 peptides in this guide (MOTS-c and Epitalon) are on the FDA Pharmacy Compounding Advisory Committee (PCAC) advisory docket for July 23–24, 2026. The PCAC makes recommendations — the FDA issues final rules later. Full regulatory status →
| Peptide | Cluster | Energy mechanism | Evidence | 2026 regulatory |
|---|---|---|---|---|
| CJC-1295 | GH-Axis | GH elevation drives IGF-1-mediated lipolysis — hormone-sensitive lipase (HSL) activation releases triglycerides as free fatty acids for oxidative fuel. | Moderate | Cat-2 removed Apr 2026 |
| Ipamorelin | GH-Axis | Selective GH secretagogue: strong GH pulse without co-stimulation of cortisol, ACTH, or prolactin. | Moderate | Cat-2 removed Apr 2026 |
| MOTS-c | Mitochondrial | AMPK activation promotes fatty acid oxidation (FAO) via inhibition of acetyl-CoA carboxylase → reduced malonyl-CoA → open CPT1 gate for mitochondrial fatty acid import. | Moderate | PCAC docket July 23–24, 2026 |
| Epitalon | Mitochondrial | Circadian clock genes govern the diurnal rhythms of cortisol (morning energy substrate mobilization), GH secretion (nocturnal slow-wave sleep pulses), and tissue insulin sensitivity. | Low-Moderate | PCAC docket July 23–24, 2026 |
CJC-1295 & Ipamorelin: distinct receptors, synergistic GH elevation, fat oxidation and substrate utilization
Long-acting GHRH analog — sustained GH elevation
Mechanism
Modified GHRH(1-29) with substitutions at positions 2, 8, 15, and 27 that resist DPP-IV cleavage. The DAC (Drug Affinity Complex) variant additionally binds serum albumin via a C8 fatty acid linker, extending half-life to ~7–8 days. Acts on pituitary GHRH-R to increase GH synthesis and cAMP-mediated GH release.
Energy angle
GH elevation drives IGF-1-mediated lipolysis — hormone-sensitive lipase (HSL) activation releases triglycerides as free fatty acids for oxidative fuel. GH simultaneously reduces peripheral insulin-mediated glucose uptake, shifting muscle substrate preference toward fat. Net effect: improved metabolic substrate flexibility.
Key studies
Teichman SL et al. (2006, J Clin Endocrinol Metab) — CJC-1295 with DAC produced dose-dependent 2–10x GH elevation and 1.5–3x IGF-1 elevation lasting up to 14 days in healthy adults (n=45). Alba M et al. (2006, J Clin Endocrinol Metab) confirmed similar findings in GH-deficient adults.
CJC-1295 was among the 12 peptides the FDA removed from Category 2 in April 2026. This does not authorize compounding or constitute FDA approval. Full regulatory status →
Selective GHSR-1a agonist — clean GH pulse
Mechanism
Pentapeptide amide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a highly selective agonist at the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Triggers pulsatile GH release through a distinct intracellular signaling pathway from GHRH-R — making it synergistic with CJC-1295 rather than redundant.
Energy angle
Selective GH secretagogue: strong GH pulse without co-stimulation of cortisol, ACTH, or prolactin. This selectivity matters for energy — GHRP-6 produces comparable GH release but with a significant cortisol spike that partially opposes the lipolytic and anabolic benefits. Ipamorelin's clean pulse allows GH-mediated fat oxidation without cortisol counter-regulation.
Key studies
Raun K et al. (1998, Eur J Endocrinol) — established ipamorelin's selectivity profile in dose-escalation studies: potent GH release with no meaningful change in ACTH, cortisol, prolactin, or aldosterone. Svensson J et al. (1998) demonstrated synergy with GHRH — the combination produced greater GH amplitude than either alone.
Ipamorelin was among the 12 peptides the FDA removed from Category 2 in April 2026. This does not authorize compounding or constitute FDA approval. Full regulatory status →
CJC-1295 and Ipamorelin act through distinct receptors (GHRH-R and GHSR-1a respectively), making them mechanistically synergistic rather than redundant. CJC-1295 provides sustained GHRH-R stimulation that amplifies the pituitary's readiness to release GH; Ipamorelin then triggers a pulsatile GHSR-1a-mediated release. Svensson et al. (1998) demonstrated that combining a GHRH analog with a GHSR agonist produces greater GH amplitude than either alone — the GHRH signal primes the somatotroph cell while the ghrelin receptor signal provides the release trigger. This is conceptually analogous to combining a primer and trigger: one without the other is incomplete. The research literature frequently studies these compounds together, and vendors commonly sell them as a stack. COA verification of both compounds is independently valuable — the combined product market has historically had quality control challenges.
MOTS-c & Epitalon: AMPK-driven bioenergetics and pineal clock restoration
Mitochondrial-derived peptide — AMPK activator
Mechanism
16-amino-acid peptide encoded within the 12S ribosomal RNA gene of the mitochondrial genome — one of the first peptides discovered to be encoded by mitochondrial DNA and act as a systemic signaling molecule. Translocates to the nucleus under metabolic stress to activate AMPK via folate-methionine cycle metabolites (accumulation of AICAR, a direct AMPK activator).
Energy angle
AMPK activation promotes fatty acid oxidation (FAO) via inhibition of acetyl-CoA carboxylase → reduced malonyl-CoA → open CPT1 gate for mitochondrial fatty acid import. Upregulates PGC-1α → mitochondrial biogenesis. Improves insulin-independent glucose uptake in skeletal muscle (GLUT4). Acts as an exercise mimetic — circulating MOTS-c rises with acute exercise.
Key studies
Lee C et al. (2015, Cell Metabolism) — first characterization; MOTS-c improved insulin sensitivity and reduced adiposity in HFD mouse models without reduced food intake. Kim SJ et al. (2018, PNAS) — MOTS-c declines with age; administration to aged mice restored metabolic flexibility and improved physical performance. Miller B et al. (2021, Aging) — pilot human study showing elevated plasma MOTS-c and exercise-stimulated metabolic markers after injection.
MOTS-c is on the FDA PCAC advisory docket for July 23–24, 2026. The PCAC reviews nominations and makes recommendations — the FDA issues final rules later. Full regulatory status →
Pineal tetrapeptide — circadian clock and metabolic rhythm restoration
Mechanism
Tetrapeptide (Ala-Glu-Asp-Gly) derived from Epithalamin, isolated from bovine pineal gland. Acts on the pineal gland to restore melatonin synthesis rhythm and reactivate expression of core circadian clock genes (Per1, Per2, Bmal1, Clock) in aged tissue. Separately activates telomerase (hTERT upregulation) in somatic cells and suppresses reactive oxygen species (ROS).
Energy angle
Circadian clock genes govern the diurnal rhythms of cortisol (morning energy substrate mobilization), GH secretion (nocturnal slow-wave sleep pulses), and tissue insulin sensitivity. Age-related pineal decline disrupts these rhythms, producing a characteristic fatigue pattern — poor morning cortisol rise, blunted nocturnal GH, and flattened metabolic oscillations. Epitalon research suggests clock gene restoration partially reverses this phenotype.
Key studies
Khavinson VKh & Anisimov VN (2010, Ageing Res Rev) — comprehensive review of two decades of Epitalon data; documented clock gene restoration, melatonin rhythm normalization, and antioxidant effects. Anisimov VN et al. (2003, J Gerontol Biol Sci) — lifespan extension and improved physiological age markers in Sprague-Dawley rats. Human data: Russian-language clinical studies from the 1990s–2000s showing improved functional markers in elderly subjects; limited independent Western replication.
Epitalon is on the FDA PCAC advisory docket for July 23–24, 2026. The PCAC reviews nominations and makes recommendations — the FDA issues final rules later. Full regulatory status →
In April 2026 the FDA removed 12 peptides from Category 2; this does not place them on the Category 1 (503A) list or authorize compounding. The PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations — the FDA issues any final rule later.
Removed from FDA Category 2 in April 2026. Not on July 23–24, 2026 PCAC docket. Regulatory gray zone — not authorized for compounding.
Full statusRemoved from FDA Category 2 in April 2026. Not on July 23–24, 2026 PCAC docket. Regulatory gray zone — not authorized for compounding.
Full statusOn the July 23–24, 2026 FDA PCAC advisory docket. Under active review for potential 503A placement. PCAC is advisory — the FDA issues final rules later.
Full statusOn the July 23–24, 2026 FDA PCAC advisory docket. Under active review for potential 503A placement. PCAC is advisory — the FDA issues final rules later.
Full statusMOTS-c, Epitalon, CJC-1295, and Ipamorelin are all available from research vendors with documented third-party testing — but COA quality varies widely. Key signals to check:
Best Peptides for Longevity
Epitalon and MOTS-c longevity angle — telomere biology, lifespan extension data, and the anti-aging evidence base.
Best Peptides for Muscle Growth
CJC-1295, Ipamorelin, and GH secretagogue stack research — the muscle-building angle vs. this guide's energy/metabolism focus.
Best Peptides for Sleep
Epitalon, DSIP, CJC-1295, and Ipamorelin in the sleep context — nocturnal GH pulses and circadian reset from a sleep lens.
Best Peptides for Cognitive Function
Semax, Selank, Dihexa — BDNF, neuroplasticity, and the cognitive energy overlap with mitochondrial support peptides.
FDA 2026 Regulatory Alerts
April 2026 Category 2 removal and July PCAC docket — what it means for CJC-1295, Ipamorelin, MOTS-c, and Epitalon.
Energy-relevant peptide research spans two mechanistic clusters. The first targets mitochondrial bioenergetics — MOTS-c activates AMPK through a folate-methionine cycle intermediate, driving mitochondrial fatty acid oxidation and glucose utilization; Epitalon restores pineal-mediated circadian rhythmicity, which governs cortisol and metabolic hormone cycles that regulate daytime energy availability. The second cluster targets the GH axis: CJC-1295 is a modified GHRH (growth hormone releasing hormone) analog that elevates pituitary GH secretion, which drives IGF-1-mediated lipolysis and shifts substrate utilization toward fat oxidation; Ipamorelin is a selective GHSR-1a agonist (ghrelin receptor) that triggers pulsatile GH release without the cortisol, prolactin, or ACTH co-stimulation seen with older GH secretagogues like GHRP-6. Both clusters share a common downstream outcome: improved metabolic substrate flexibility — the capacity to efficiently switch between fat and glucose as fuel — which is a primary determinant of sustained energy output rather than transient stimulant effect. All four are research compounds; none are approved for fatigue, energy enhancement, or any human indication.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — one of the first peptides discovered to be encoded by mitochondrial DNA rather than nuclear DNA. Its energy-relevant mechanism begins in the mitochondrial matrix, where under metabolic stress, specific folate cycle metabolites (particularly AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide) accumulate due to MOTS-c's effect on the folate-methionine pathway. AICAR is a well-characterized direct activator of AMP-activated protein kinase (AMPK), the master energy sensor of the cell. AMPK activation has downstream effects specific to energy metabolism: it promotes fatty acid oxidation (FAO) by inhibiting acetyl-CoA carboxylase and malonyl-CoA production (which normally blocks entry of fatty acids into the mitochondria for beta-oxidation); it upregulates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis; and it improves glucose uptake in skeletal muscle via GLUT4 translocation independent of insulin. Lee et al. (2015, Cell Metabolism) first characterized MOTS-c in this context, demonstrating that administration improved insulin sensitivity and reduced obesity in high-fat diet mouse models without changes in food intake — a metabolic improvement without caloric restriction. Kim et al. (2018, PNAS) showed that MOTS-c levels decline with age in both rodents and humans, and that administration to aged mice restored metabolic flexibility and improved physical performance. A small human pilot study (Miller et al., 2021, Aging) demonstrated that exogenous MOTS-c injection increased circulating MOTS-c and elevated exercise-stimulated metabolic markers, though large-scale human trials are absent.
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a natural polypeptide isolated from the bovine pineal gland by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in the 1970s. While Epitalon is widely discussed in the context of telomere biology — it activates telomerase (hTERT) in somatic cells — its most direct mechanism relevant to energy is through circadian rhythm restoration. The pineal gland regulates the master circadian oscillator by producing melatonin in a light-dependent cycle; this rhythm entrains peripheral circadian clocks in metabolic tissues including the liver, muscle, and adipose tissue. As the pineal gland ages, its functional output declines: melatonin amplitude decreases and circadian melatonin rhythmicity dampens. Khavinson et al. demonstrated that Epitalon restores expression of core circadian clock genes — Per1, Per2, Bmal1, and Clock — in aged pineal tissue, effectively resetting the molecular clock in animals with disrupted circadian function. This matters for energy because the hypothalamic-pituitary-adrenal (HPA) axis, GH secretion patterns, cortisol diurnal rhythm, and substrate utilization (carbohydrate vs. fat) are all clock-controlled: cortisol peaks in the morning to mobilize energy substrate; GH pulses are largest during slow-wave sleep; insulin sensitivity varies by time of day. Disruption of these circadian patterns — seen in aging, shift work, and pineal dysfunction — produces a fatigued metabolic state that Epitalon research suggests may be partially reversible by restoring the upstream circadian signal. Anisimov et al. (2003, J Gerontol Biol Sci) documented lifespan extension and improved physiological age markers in mice receiving Epitalon. Human data derives primarily from Russian-language clinical studies from the 1990s–2000s, with limited independent replication in peer-reviewed Western journals.
CJC-1295 and Ipamorelin both elevate GH secretion but through distinct receptors, producing synergistic effects when combined. CJC-1295 is a modified analog of GHRH (growth hormone releasing hormone, residues 1–29), with amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to dipeptidyl peptidase IV cleavage, substantially extending half-life. The variant with a Drug Affinity Complex (DAC) — trans-3-hexadecenoic acid attached via a lysine linker at position 8 — binds circulating albumin, further extending bioavailability to approximately 7–8 days. Teichman et al. (2006, J Clin Endocrinol Metab) demonstrated dose-dependent 2–10x increases in mean GH plasma concentration and 1.5–3x increases in IGF-1 in healthy adults (n=45), with effects persisting up to 14 days after a single injection of the DAC version. The energy-relevant pathway: elevated GH acts on adipocytes to stimulate lipolysis — hormone-sensitive lipase (HSL) activation releases stored triglycerides as free fatty acids (FFAs) into circulation as metabolic fuel; GH simultaneously reduces peripheral insulin-mediated glucose uptake, directing glucose toward tissues with obligate glucose requirements (brain, red blood cells) while diverting muscle to preferential fat oxidation. The net effect on energy physiology is improved substrate utilization efficiency — the body burns more fat for steady-state energy rather than relying exclusively on glycolytic flux. Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) acts through a completely different receptor: GHSR-1a (the growth hormone secretagogue receptor / ghrelin receptor), which is expressed in the pituitary and hypothalamus. Raun et al. (1998, Eur J Endocrinol) characterized Ipamorelin as a highly selective GH secretagogue: it produces strong, pulsatile GH release with no meaningful increase in cortisol, ACTH, prolactin, or aldosterone — in contrast to GHRP-6, which strongly elevates cortisol (an energy-opposing catabolic stress hormone). This selectivity makes ipamorelin's GH pulse 'clean' from an energy standpoint: the anabolic and lipolytic benefits of GH elevation without a concurrent cortisol surge that would blunt those effects.
The DAC (Drug Affinity Complex) modification determines the pharmacokinetic profile of CJC-1295 without changing its receptor interaction profile. Both versions are GHRH receptor agonists — they bind the GHRH-R on somatotroph cells in the anterior pituitary and stimulate GH synthesis and release through the same cAMP-PKA signaling cascade. The difference is half-life and therefore the pattern of GH secretion they produce. CJC-1295 without DAC (also marketed as Modified GRF(1-29) or Mod GRF 1-29) has a half-life of approximately 30 minutes — substantially longer than native GHRH(1-44) which is degraded within 7 minutes by dipeptidyl peptidase IV in circulation. This 30-minute window allows a more sustained GHRH receptor stimulation that amplifies a GH pulse but still follows a pulsatile pattern. CJC-1295 with DAC has the trans-3-hexadecenoic acid moiety that allows reversible covalent binding to serum albumin, extending the half-life to approximately 7–8 days per Teichman et al. (2006). This creates blunted but sustained GH elevation over days — essentially a continuous low-amplitude GHRH signal rather than a pulsatile one. Physiologically normal GH secretion is pulsatile (large nocturnal pulses during slow-wave sleep), and some researchers have raised the question of whether chronic low-level GHRH stimulation disrupts normal pulse architecture. This pharmacokinetic distinction is a frequent point of discussion in the research community, though large comparative human trials directly addressing pulse architecture effects have not been conducted.
GHRP-6 (Growth Hormone Releasing Peptide-6) was one of the earliest GH secretagogues studied and produces robust GH release, but its selectivity profile creates problems for energy-focused research: GHRP-6 produces significant elevations in cortisol and prolactin co-released alongside GH. Cortisol is a counter-regulatory stress hormone with direct energy-opposing effects — it promotes gluconeogenesis (raising blood glucose, which triggers insulin release, which inhibits fat oxidation), promotes muscle protein catabolism (muscle is an energy substrate reservoir the body sacrifices under stress), and suppresses the parasympathetic nervous system (which is important for recovery and sleep quality). A GH pulse accompanied by a cortisol spike partially cancels the energy benefits of GH by simultaneously activating stress-axis metabolic pathways. GHRP-2 has a similar but somewhat attenuated cortisol/ACTH stimulation profile. Ipamorelin, by contrast, was specifically selected in the Raun et al. (1998) screening program for its selectivity: among a library of novel GH secretagogue analogs, ipamorelin was notable for producing GH release with no meaningful change in cortisol, ACTH, aldosterone, or prolactin. The hexapeptide structure (pentapeptide amide) achieves this by engaging GHSR-1a in a way that preferentially recruits the GH-releasing signaling pathway without sufficient receptor activation to trigger the secondary HPA-axis pathways that GHRP-6 engages. GHRP-2 also has lower cortisol elevation than GHRP-6 but is not as selective as ipamorelin. The net result for energy-focused research: ipamorelin's GH pulse is 'clean' — the downstream lipolytic and substrate-metabolism benefits occur without simultaneous cortisol-mediated energy-opposing signals.
All four peptides are sold as research chemicals in the United States — none hold FDA approval for any energy, metabolism, fatigue, or other human indication. Their 2026 regulatory positions differ. CJC-1295 and Ipamorelin are among the 12 peptides the FDA removed from Category 2 (the significant-safety-concern list for 503B bulk drug substances) in April 2026. This removal places them in a regulatory gray zone: it does not constitute FDA approval, does not place them on the Category 1 (503A compoundable) list, and does not authorize compounding — it only removes the specific 'significant safety risk' barrier. CJC-1295 and Ipamorelin are not currently on the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) advisory docket. MOTS-c and Epitalon were not among the April 2026 Category 2 removals but are separately on the July 23–24, 2026 PCAC advisory docket — meaning they are in active review for potential 503A Bulk Drug Substance list placement, which would allow licensed 503A compounding pharmacies to compound them if the FDA issues a favorable final rule after the advisory meeting. The PCAC makes recommendations; the FDA issues final rules, typically 6–18 months after an advisory meeting. None of these regulatory positions constitute FDA approval, authorization of therapeutic use, or endorsement of efficacy for energy or any other indication. Compounding pharmacies, telehealth providers, and healthcare professionals should consult current FDA guidance and legal counsel. Individuals should consult a licensed healthcare provider.
MOTS-c and NAD+ precursors (NMN, NR) target mitochondrial energy metabolism through distinct upstream mechanisms, making them more complementary than competitive. NAD+ precursors work by replenishing the NAD+/NADH pool — the cofactor required for the electron transport chain (Complex I), the TCA cycle (isocitrate dehydrogenase, malate dehydrogenase, alpha-ketoglutarate dehydrogenase), and sirtuin-mediated metabolic regulation (SIRT1, SIRT3). NAD+ depletion is a well-documented feature of aging, and precursor supplementation demonstrably restores intracellular NAD+ levels in human trials. MOTS-c's mechanism is upstream and regulatory rather than stoichiometric: it does not supply a substrate to the electron transport chain but instead activates AMPK — the energy sensor that monitors the AMP/ATP ratio and upregulates mitochondrial biogenesis and fat oxidation when cellular energy is perceived as low. AMPK and SIRT1 (NAD+-dependent) actually form a feedback loop: AMPK activates SIRT1 via NAD+ upregulation, and SIRT1 deacetylates PGC-1α, the master mitochondrial biogenesis transcription factor. So MOTS-c (AMPK) and NAD+ (SIRT1) can converge on the same downstream outcome (PGC-1α activation and mitochondrial biogenesis) through overlapping but non-identical pathways. The comparison pairs `/peptides/compare/mots-c-vs-nad-plus` and `/peptides/compare/epitalon-vs-nad-plus` on this platform present head-to-head COA quality data for vendors selling each compound, which is a more operationally useful differentiator than mechanism alone for research procurement decisions.
Disclosed Labs